CCL13 抗体 (AA 24-98)
-
- 抗原 See all CCL13 抗体
- CCL13 (Chemokine (C-C Motif) Ligand 13 (CCL13))
-
抗原表位
- AA 24-98
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This CCL13 antibody is un-conjugated
-
应用范围
- Neutralization (Neut), Flow Cytometry (FACS)
- 产品特性
- Mouse anti human CCL-13
- 免疫原
- AA 24-98
- 克隆位点
- MM0137-3G14
- 亚型
- IgG1
- Top Product
- Discover our top product CCL13 Primary Antibody
-
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) (AA 24-98) antibody
CCL13 适用: 人 WB, IHC, IP, ICC 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) antibodyCCL13 适用: 人 ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) antibodyCCL13 适用: 人, 小鼠, 大鼠 WB, ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) (AA 17-81) antibodyCCL13 适用: 人 ELISA, IHC 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) antibodyCCL13 适用: 人 WB, ELISA 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) (AA 1-98) antibodyCCL13 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) (AA 1-98) antibodyCCL13 适用: 人 WB 宿主: 小鼠 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) (C-Term) antibodyCCL13 适用: 人 WB 宿主: 兔 Polyclonal unconjugated
anti-Chemokine (C-C Motif) Ligand 13 (CCL13) (AA 24-98) antibodyCCL13 适用: 人 WB, ELISA, IHC, IF/ICC 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
- Optimal dilutions should be determined by each laboratory for each application.
- 限制
- 仅限研究用
-
- 状态
- Lyophilized
- 溶解方式
- 200 µL of PBS, pH 7.4
- 浓度
- 500 µg/mL
- 缓冲液
- Lyophilized from a solution containing PBS, pH 7.4
- 储存条件
- -20 °C
-
- 抗原
- CCL13 (Chemokine (C-C Motif) Ligand 13 (CCL13))
- 别名
- CCL-13 (CCL13 产品)
- 别名
- CKb10 antibody, MCP-4 antibody, NCC-1 antibody, NCC1 antibody, SCYA13 antibody, SCYL1 antibody, C-C motif chemokine ligand 13 antibody, chemokine (C-C motif) ligand 13 antibody, CCL13 antibody
- UniProt
- Q99616
- 途径
- Regulation of Systemic Arterial Blood Pressure by Hormones, The Global Phosphorylation Landscape of SARS-CoV-2 Infection
-
